PIK3CA
PIK3CA encodes the catalytic p110α subunit of class I phosphoinositide 3-kinase (PIK3CA), a central signaling enzyme in pathways that regulate cell growth, survival, metabolism, and proliferation.
PIK3CA encodes the catalytic p110α subunit of class I phosphoinositide 3-kinase (PIK3CA), a central signaling enzyme in pathways that regulate cell growth, survival, metabolism, and proliferation. As a protein target, PIK3CA is especially important in oncology because activating mutations can drive aberrant Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) signaling and contribute to tumor progression and therapy resistance.
In biomedical research, PIK3CA is frequently studied as a drug target for selective PIK3CA inhibition. This is particularly relevant in cancers such as cervical cancer and breast cancer, where mutant PIK3CA can create a dependency on PIK3CA signaling. Recent studies also place PIK3CA within broader pathway networks involving EGFR/SRC-mediated EMT, KRAS, mitogen-activated protein kinase 1 (MAPK1), PTGS2, and the PI3K/Akt signaling pathway, underscoring its role as a hub in oncogenic signaling.
Where the papers sit
14 papers from the last 6 months study PIK3CA directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 4 observational · 4 human data · 5 preclinical · 1 unclassified
Themes one subject
Those 14 are all about one subject.
-
Broad Molecular Oncology
PIK3CA-linked cancer biology sits alongside broader molecular oncology, spanning multi-omics, liquid-biopsy profiling and individualized tumor-board assessment. Recurrent mechanisms include PI3Kα-inhibitor adaptation, E545A-driven proliferation and resistance to Alpelisib, IRF1-NLRC5-MHC-I immune activation, and KAT6A/H3K23ac/TRIM24 regulation of ferroptosis. Other entries address neoantigen design, SMARCA2/4-deficient subtypes, breast cancer brain metastases, macrophage immunosuppression and androgen-receptor agonism. No single therapeutic direction unifies the set.
Papers
The 14 papers from the last 6 months that study PIK3CA directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Broad Molecular Oncology (14)
- Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients. PLoS biology · 5 Oct 2026 PMID 42832529
- NeoGen-BC: A synergistic framework combining generative protein language models and multi-window deep learning for designing shared neoantigens in breast cancer. Biochemical and biophysical research communications · 10 Sept 2026 PMID 42721858
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. Oncotarget · 21 Jul 2026 PMID 42478852
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
- Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma. Journal for immunotherapy of cancer · 7 Jul 2026 PMID 42413983
- Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib. Biochemical and biophysical research communications · 24 Jun 2026 PMID 42341421
- TRERNA1-mediated acetylation represses ferroptosis of non-small cell lung cancer cells via the KAT6A/H3K23ac/TRIM24-PIK3CA pathway. Human cell · 24 Jun 2026 PMID 42340519
- Renal vein thrombosis as a reversible vascular renal complication of CLOVES syndrome: a case report. CEN case reports · 23 Jun 2026 PMID 42334730
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
- Comparative metabolomic profiling and potential bioactive marker discovery of three Clerodendrum species and their different plant parts. Fitoterapia · 3 Jun 2026 PMID 42235855
- (Phospho)proteomic Profiling Reveals Mutation-Specific Adaptive Signaling to PI3Kα Inhibition in PIK3CA Mutant Breast Epithelial Cells. Journal of proteome research · 28 May 2026 PMID 42204977
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine · 22 May 2026 PMID 42173096
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
By study type
Observational studies and case reports (4)
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. Oncotarget · 21 Jul 2026 PMID 42478852
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
- Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma. Journal for immunotherapy of cancer · 7 Jul 2026 PMID 42413983
- Renal vein thrombosis as a reversible vascular renal complication of CLOVES syndrome: a case report. CEN case reports · 23 Jun 2026 PMID 42334730
Human data, design not indexed (4)
- Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients. PLoS biology · 5 Oct 2026 PMID 42832529
- NeoGen-BC: A synergistic framework combining generative protein language models and multi-window deep learning for designing shared neoantigens in breast cancer. Biochemical and biophysical research communications · 10 Sept 2026 PMID 42721858
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
Preclinical: animal, cell and lab studies (5)
- Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib. Biochemical and biophysical research communications · 24 Jun 2026 PMID 42341421
- TRERNA1-mediated acetylation represses ferroptosis of non-small cell lung cancer cells via the KAT6A/H3K23ac/TRIM24-PIK3CA pathway. Human cell · 24 Jun 2026 PMID 42340519
- Comparative metabolomic profiling and potential bioactive marker discovery of three Clerodendrum species and their different plant parts. Fitoterapia · 3 Jun 2026 PMID 42235855
- (Phospho)proteomic Profiling Reveals Mutation-Specific Adaptive Signaling to PI3Kα Inhibition in PIK3CA Mutant Breast Epithelial Cells. Journal of proteome research · 28 May 2026 PMID 42204977
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine · 22 May 2026 PMID 42173096
Unclassified: not yet indexed with MeSH (1)
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.